Zoetis Inc. (ZTS)
| Market Cap | 70.87B |
| Revenue (ttm) | 9.29B |
| Net Income (ttm) | 2.52B |
| Shares Out | 445.21M |
| EPS (ttm) | 5.57 |
| PE Ratio | 28.58 |
| Forward PE | 25.11 |
| Dividend | $2.00 (1.26%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 1,375,165 |
| Open | 158.05 |
| Previous Close | 159.08 |
| Day's Range | 157.61 - 159.47 |
| 52-Week Range | 139.70 - 200.33 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 211.50 (+32.87%) |
| Earnings Date | Aug 5, 2025 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $211.5, which is an increase of 32.87% from the latest price.
News
Zoetis: Growth To Continue Thanks To Companion Animals
Zoetis remains a compelling long-term investment, driven by strong growth in companion animal products and a resilient pet care market. Despite recent underperformance and valuation concerns, Zoetis's...
Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin P...
Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.
The Merck rival faces intense competition that could limit multiple expansion, Stifel analysts say.
Top Stock Movers Now: Jabil, Oracle, Zoetis, and More
U.S. equities were higher at midday as President Donald Trump again called on Federal Reserve Chair Jerome Powell to cut interest rates ahead of today's Fed decision. The Dow Jones Industrial Average,...
Zoetis Releases 2024 Sustainability Progress Update
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis published its 2024 Sustainability Progress Update “Advancing Sustainability in Animal Health for a Better Future” to highlight the comp...
Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript)
Zoetis Inc. (NYSE:ZTS) William Blair 45th Annual Growth Stock Conference June 3, 2025 11:40 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Brandon Vazquez - William Blai...
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
Top 15 High-Growth Dividend Stocks For June 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, thoug...
Zoetis Inc. (ZTS) Stifel 2025 Jaws & Paws Conference (Transcript)
Zoetis Inc. (NYSE:ZTS) Stifel 2025 Jaws & Paws Conference May 29, 2025 9:10 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Jon Block - Stifel Jon Blo...
Dr. Mark Stetter Elected to Zoetis Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual share...
Zoetis Declares Third Quarter 2025 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will b...
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Pari...
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Zoetis' Q1: Market Overreaction Or Justified Drop?
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of...
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company ...
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny J...
Zoetis raises forecast for 2025 revenue, profit on weaker US dollar
Animal healthcare company Zoetis on Tuesday raised its forecasts for annual adjusted profit and revenue above Wall Street expectations, after beating first-quarter estimates, benefiting from a weak U....
Zoetis Announces First Quarter 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company...
Zoetis: Unleashing Margin Expansion; Initiate Strong Buy
We initiate coverage on Zoetis with a Strong Buy rating and a $219.26 price target, driven by explosive growth in companion animal products and structural margin expansion. Zoetis's leadership in comp...
Elanco vs Zoetis stock: Sarat Sethi picks a side
Zoetis Inc (NYSE: ZTS) is a relatively better pick than Elanco Animal Health Inc (NYSE: ELAN) for those interested in gaining exposure to the pets category, says Sarat Sethi. He's a managing partner a...
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
My Top 15 High-Growth Dividend Stocks For April 2025
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% ...
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck...
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humaniza...